NCT04046939 (EXHALE-1) is a Phase 2 clinical trial of Dexpramipexole in Eosinophilic Asthma, sponsored by Knopp Biosciences.

Who is sponsoring NCT04046939?

NCT04046939 is sponsored by Knopp Biosciences.

What drugs are being tested in NCT04046939?

Interventions in NCT04046939: Dexpramipexole, Placebo.

What condition does NCT04046939 study?

NCT04046939 studies Eosinophilic Asthma, Asthma.

Is NCT04046939 still recruiting?

NCT04046939 is currently completed. Last updated 13 April 2023.

Are results published for NCT04046939?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-04-13 · How we verify

NCT04046939: EXHALE-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

Completed Phase 2 Results posted Last updated 13 April 2023

What this trial tests

Phase 2 trial testing Dexpramipexole in Eosinophilic Asthma in 534 participants. Completed in 2 March 2021.

Timeline

15 August 2019

Primary endpoint
3 December 2020

2 March 2021

Quick facts

Lead sponsor	Knopp Biosciences
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	534
Start date	15 August 2019
Primary completion	3 December 2020
Estimated completion	2 March 2021
Sites	36 locations across United States

Drugs / interventions tested

Dexpramipexole — full drug profile →
Placebo

Conditions studied

Eosinophilic Asthma — all drugs for Eosinophilic Asthma →
Asthma — all drugs for Asthma →

Sponsor

Knopp Biosciences — full company profile →

Who can join

Adults 18 to 74, any sex, with Eosinophilic Asthma or Asthma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Blood Absolute Eosinophil Count From Baseline to Week 12 Primary · Baseline, 12 Weeks

The primary endpoint of this study was the change in AEC from Baseline to Week 12 on a ratio scale. The analysis used a mixed effects model repeated-measures (MMRM) with terms for log10 transformed baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and log10 transformed baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the log10 transformed post-baseline value minus the log10 transformed baseline value. The estimates of Geometric LS Means and their ratios were obtai

Group	Value	95% CI
Placebo BID	0.8980	± 1.26
37.5 mg BID Dexpramipexole	0.4031	± 1.28
75 mg BID Dexpramipexole	0.3056	± 1.27
150 mg BID Dexpramipexole	0.2051	± 1.25

Change in Pre-bronchodilator FEV1 (Liters) From Baseline to Week 12 Secondary · Baseline, 12 Weeks

FEV1 is defined as the amount of air that can be forcibly exhaled from the lungs in the first second of a forced exhalation.

Group	Value	95% CI
Placebo BID	0.0700	± 0.08329
37.5 mg BID Dexpramipexole	0.208	± 0.08387
75 mg BID Dexpramipexole	0.0557	± 0.07848
150 mg BID Dexpramipexole	0.247	± 0.07769
Combined 150 mg BID and 75 mg BID Arms	0.151	± 0.05746

Change in Asthma Control Questionnaire (ACQ-6) Score From Baseline to Week 12 Secondary · Baseline, 12 Weeks

ACQ-6 is simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment. The 6-point self-administered scale has items measuring asthma symptoms and rescue inhaler use. The ACQ score is the mean of the questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). The original protocol planned to analyze the ACQ-7 score. As a result of FEV1 testing restrictions imposed on the study during the COVID-19 pandemic, the analysis was prospectively modified to the ACQ-6 score prior to dat

Group	Value	95% CI
Placebo BID	-0.391	± 0.1866
37.5 mg BID Dexpramipexole	-0.419	± 0.1974
75 mg BID Dexpramipexole	-0.437	± 0.1924
150 mg BID Dexpramipexole	-0.655	± 0.1803

Change in Post-bronchodilator FEV1 From Baseline to Week 12 Secondary · Baseline, 12 Weeks

Post-bronchodilator FEV1 is defined as the amount of air that can be forcibly exhaled from the lungs in the first second of a forced exhalation, after treatment with inhaled albuterol.

Group	Value	95% CI
Placebo BID	-0.00546	± 0.07208
37.5 mg BID Dexpramipexole	0.0932	± 0.07455
75 mg BID Dexpramipexole	-0.000717	± 0.06977
150 mg BID Dexpramipexole	0.176	± 0.07182

Change in Quality of Life, as Measured by the Asthma Quality of Life Questionnaire (AQLQ) From Baseline to Week 12 Secondary · Baseline, 12 Weeks

The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma. The 32 questions in the AQLQ are divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli. Individual questions are equally weighted. The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.

Group	Value	95% CI
Placebo BID	0.376	± 0.1999
37.5 mg BID Dexpramipexole	0.531	± 0.2112
75 mg BID Dexpramipexole	0.312	± 0.2055
150 mg BID Dexpramipexole	0.584	± 0.1979

Number of Participants With Potentially Clinically Significant Hematology Results by Treatment Group Post Randomization Through Week 12 Secondary · Immediately post-baseline up to Week 12

Number of Participants with Potentially Clinically Significant Hematology Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.

Eosinophils >1.6 x 10^9/L

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Basophils >1.6 x 10^9/L

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Erythrocytes ≤3.5 x 10^12/L

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	1
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	2

Erythrocytes ≥6.4 x 10^12/L

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Hematocrit ≤32% - Females

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	2
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	1

Hematocrit ≥54% - Females

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Hematocrit ≤37% - Males

Group	Value	95% CI
Placebo BID	2
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	1
150 mg BID Dexpramipexole	1

Hematocrit ≥60% - Males

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Number of Participants With Potentially Clinically Significant Blood Chemistry Results by Treatment Group Post Randomization Through Week 12 Secondary · Immediately post-baseline up to Week 12

Number of Participants with Potentially Clinically Significant Blood Chemistry Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.

ALT ≥ 3 x ULN

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	1
150 mg BID Dexpramipexole	0

Albumin ≤ 2.5 g/dL

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Alkaline Phosphatase ≥ 1.5 x ULN

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	1
150 mg BID Dexpramipexole	1

AST ≥ 3 x ULN

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Bicarbonate ≤ 16 mEq/L

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	1
150 mg BID Dexpramipexole	0

Bicarbonate ≥ 35 mEq/L

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Bilirubin > 2 X ULN and (ALT or AST ≥ 3 X ULN)

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Bilirubin ≥ 1.5 x ULN

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Number of Participants With Potentially Clinically Significant Urinalysis Results by Treatment Group Post Randomization Through Week 12 Secondary · Immediately post-baseline up to Week 12

Number of Participants with Potentially Clinically Significant Urinalysis Results (glycosuria, ketonuria, or proteinuria) by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline urinalysis value in each treatment group. Patients are only counted once per criterion per laboratory test. The number of participants with potential clinical important urinalysis findings at any post-baseline visit were reported.

glycosuria (glucose in urine ++++)

Group	Value	95% CI
Placebo BID	1
37.5 mg BID Dexpramipexole	2
75 mg BID Dexpramipexole	1
150 mg BID Dexpramipexole	0

ketonuria (ketones in urine ≥ ++++)

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

proteinuria (protein in urine ≥ ++)

Group	Value	95% CI
Placebo BID	1
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Number of Participants With Potentially Clinically Significant Vital Signs Results by Treatment Group Post Randomization Through Week 12 Secondary · Immediately post-baseline up to Week 12

Number of Participants with Potentially Clinically Significant Vital Signs Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.

Systolic blood pressure: >180 mmHg

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Systolic blood pressure: Increase >40 mmHg

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Systolic blood pressure: <90 mmHg

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Systolic blood pressure: Decrease >30 mmHg

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Diastolic blood pressure: >105 mmHg

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Diastolic blood pressure: Increase >30 mmHg

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	1
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Diastolic blood pressure: <50 mmHg

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Diastolic blood pressure: Decrease >20 mmHg

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Number of Participants With Potentially Clinically Significant ECG Results by Treatment Group Post Randomization Through Week 12 Secondary · Immediately post-baseline up to Week 12

Number of Participants with Potentially Clinically Significant ECG Results by Treatment Group. Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group. Patients are only counted once per criterion per laboratory test.

Heart Rate >120 bpm

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Heart Rate Increase from Baseline >30 bpm

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	1

QT Interval: >450 ms

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

QT Interval: >480 ms

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

QT Interval: >500 ms

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

QT Interval: Increase from Baseline >30 ms

Group	Value	95% CI
Placebo BID	7
37.5 mg BID Dexpramipexole	3
75 mg BID Dexpramipexole	2
150 mg BID Dexpramipexole	0

QT Interval: Increase from Baseline >60 ms

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

QTcF Interval: >450 ms

Group	Value	95% CI
Placebo BID	0
37.5 mg BID Dexpramipexole	0
75 mg BID Dexpramipexole	0
150 mg BID Dexpramipexole	0

Change in Nasal Eosinophil Peroxidase (Presented as Ratio to Protein) From Baseline to Week 12 Secondary · Baseline, Week 12

The EPX:protein ratio was used to normalize the EPX for the quantity of sample, yielding the values in ng EPX per mg protein. The ratio of nasal Eosinophil Peroxidase to Protein is a biomarker for airway eosinophils. A lower ratio to Baseline represents a lowering in airway eosinophilia, which is a marker of successful drug therapy.

Group	Value	95% CI
Placebo BID	0.833	0.258 – 2.99
37.5 mg BID Dexpramipexole	0.645	0.275 – 1.18
75 mg BID Dexpramipexole	0.174	0 – 0.708
150 mg BID Dexpramipexole	0.110	0 – 0.943

Change in Blood Absolute Blood Basophil Count From Baseline to Week 12 Secondary · Baseline, Week 12

The analysis used a mixed effects model repeated-measures MMRM with terms for baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and baseline by visit interaction as fixed effects, and subject as a random effect. An unstructured covariance matrix was used. The response variable was the post-baseline value minus the baseline value. Basophils were enumerated as part of the WBC automated differential performed by the Central Laboratory.

Group	Value	95% CI
Placebo BID	-0.00439	± 0.006323
37.5 mg BID Dexpramipexole	-0.00655	± 0.006674
75 mg BID Dexpramipexole	-0.0250	± 0.006487
150 mg BID Dexpramipexole	-0.0277	± 0.006082

Adverse events — posted to ClinicalTrials.gov

Time frame: Placebo Run-in Period = from enrollment to Randomization (2-4 weeks); Primary Assessment Period = from Randomization through the Week 12 visit, plus 30 days following the last dose; Eosinophil Recovery Period = all visits occurring from 30 days following the last dose through the end of study (Week 24 post-Randomization). Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Screening Period

Serious: 0/103 (0%)

Deaths: 0/103

Primary Assessment Period: Placebo BID

Serious: 0/27 (0%)

Deaths: 0/27

Primary Assessment Period: 37.5 mg BID

Serious: 0/22 (0%)

Deaths: 0/22

Primary Assessment Period: 75 mg BID

Serious: 0/26 (0%)

Deaths: 0/26

Primary Assessment Period: 150 mg BID

Serious: 0/28 (0%)

Deaths: 0/28

Eosinophil Recovery Period: Assigned to Placebo BID During Primary Assessment Period

Serious: 0/25 (0%)

Deaths: 0/25

Eosinophil Recovery Period: Assigned to 37.5 mg BID During Primary Assessment Period

Serious: 0/22 (0%)

Deaths: 0/22

Eosinophil Recovery Period: Assigned to 75 mg BID During Primary Assessment Period

Serious: 0/24 (0%)

Deaths: 0/24

Eosinophil Recovery Period: Assigned to 150 mg BID During Primary Assessment Period

Serious: 0/28 (0%)

Deaths: 0/28

Other adverse events (62 terms — click to expand)

Reaction	System	Screening Period	Primary Assessment Period:…	Primary Assessment Period:…	Primary Assessment Period:…	Primary Assessment Period:…	Eosinophil Recovery Period…	Eosinophil Recovery Period…	Eosinophil Recovery Period…	Eosinophil Recovery Period…
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—
Coronavirus test positive	Investigations	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Asthma	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Monocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—
Sinus Bradycardia	Congenital, familial and genetic disorders	—	—	—	—	—	—	—	—	—
Ear pain	Ear and labyrinth disorders	—	—	—	—	—	—	—	—	—
Abdominal discomfort	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Aphthous ulcer	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Chest discomfort	General disorders	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—
Peripheral swelling	General disorders	—	—	—	—	—	—	—	—	—
Cholecystitis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—
Anaphylactic reaction	Immune system disorders	—	—	—	—	—	—	—	—	—
Acute sinusitis	Infections and infestations	—	—	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—	—	—
Corona virus infection	Infections and infestations	—	—	—	—	—	—	—	—	—
Ear infection fungal	Infections and infestations	—	—	—	—	—	—	—	—	—
Otitis externa	Infections and infestations	—	—	—	—	—	—	—	—	—
Sinusitis	Infections and infestations	—	—	—	—	—	—	—	—	—
Urethritis	Infections and infestations	—	—	—	—	—	—	—	—	—
Viral upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—
Foreign body in ear	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—
Scratch	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—
Skin laceration	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—
Sunburn	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—
Tooth fracture	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—
Fluid retention	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Intervertebral disc protrusion	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—

Data from ClinicalTrials.gov NCT04046939 adverse events section.

Sponsor's own description

This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Regulation of Eosinophilia in Asthma-New Therapeutic Approaches for Asthma Treatment.
Cusack RP, Whetstone CE, Xie Y, Ranjbar M, et al · · 2021 · cited 22× · PMID 33917396 · DOI 10.3390/cells10040817
Urine eosinophil-derived neurotoxin: A potential marker of activity in select eosinophilic disorders.
Makiya MA, Khoury P, Kuang FL, Mata AD, et al · · 2023 · cited 15× · PMID 35971862 · DOI 10.1111/all.15481
Recent advances in understanding the role of eosinophils.
Constantine GM, Klion AD. · · 2022 · cited 13× · PMID 36225210 · DOI 10.12703/r/11-26
Lessons learned from targeting eosinophils in human disease.
Kuang FL, Bochner BS. · · 2021 · cited 9× · PMID 33891135 · DOI 10.1007/s00281-021-00849-w
Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma.
Calzetta L, Aiello M, Frizzelli A, Pistocchini E, et al · · 2022 · cited 7× · PMID 36140430 · DOI 10.3390/biomedicines10092330

Verify or expand the search:

Other trials of Dexpramipexole

Trials testing the same drug.

NCT02101138 — Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome · Phase 2 · unknown

Other recruiting trials for Eosinophilic Asthma

Currently open trials in the same condition.

NCT06750289 — Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontroll · Phase 3 · recruiting
NCT04538937 — Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Charact · recruiting

Other Knopp Biosciences trials

Trials by the same sponsor.

NCT00647296 — Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04046939 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Knopp Biosciences
Last refreshed: 13 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04046939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing